Anti-glyco-MUC1 antibodies and their uses
US12065504B2 · kind B2 · utility
0Cited by
6References
32Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 29, 2021 |
| Grant date | Aug 20, 2024 |
| Priority date | — |
| Expiry date | Sep 28, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4725
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.